Form 4: CytomX CBO Rachael Lester Granted 120,000 Equity Awards

CytomX Therapeutics' Chief Business Officer, Rachael Lester, received significant equity grants including restricted stock units, stock options, and performance stock units, aligning her incentives with long-term company performance.

Summary

• Rachael Lester, Chief Business Officer of CytomX Therapeutics, Inc. (CTMX), was granted 20,000 Restricted Stock Units (RSUs) on February 2, 2026.
• Each RSU entitles the reporting person to receive one share of Common Stock upon vesting, with 1/3rd vesting annually on March 15, starting March 15, 2027, contingent on continued service.
• Lester also received an option to buy 50,000 shares of Common Stock at an exercise price of $6.09 per share, granted on February 2, 2026.
• The stock option vests at a rate of 1/48th monthly from February 2, 2026, becoming fully vested on the fourth anniversary of the grant date (February 2, 2030), subject to continued service.
• Additionally, 50,000 Performance Stock Units (PSUs) were granted on February 2, 2026, where each PSU represents a contingent right to receive one share of Common Stock upon vesting.
• The PSUs vest in three equal tranches (1/3 each) upon the achievement of specific clinical milestones, also subject to continued service.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive commitment and aligns management incentives with long-term shareholder value, which is a healthy sign for corporate governance.

Positives

• The equity grants align the Chief Business Officer's incentives with the long-term performance and success of CytomX Therapeutics.
• The vesting schedules, particularly for PSUs tied to clinical milestones, encourage the achievement of strategic corporate objectives.

Negatives

• The grants do not represent an immediate cash benefit to the executive or the company.
• Vesting of a significant portion of the equity is contingent on future service and clinical milestones, introducing an element of uncertainty regarding the ultimate realization of the awards.

Risks

• The value of the granted equity awards is subject to the future market price fluctuations of CytomX Therapeutics' common stock.
• Failure to achieve the specified clinical milestones could result in the forfeiture of the Performance Stock Units.
• The executive's departure from the company prior to vesting dates would result in the forfeiture of unvested RSUs, stock options, and PSUs.

Future Outlook

The future outlook for these equity awards is directly tied to Rachael Lester's continued service to CytomX Therapeutics and the company's ability to achieve specific clinical milestones for the Performance Stock Units. The stock options will fully vest over four years, and RSUs will vest annually over three years.

Industry Context

StockSavvy.ai notes that the granting of equity awards, including RSUs, stock options, and PSUs, is a standard and widely adopted practice in the biotechnology and pharmaceutical industries for executive compensation. This structure is designed to attract, retain, and motivate key personnel by aligning their financial interests with the long-term success and shareholder value creation of the company, particularly in a sector where long development cycles and milestone achievements are critical.

Comparison to Industry Standards

• The use of a mix of time-based (RSUs, stock options) and performance-based (PSUs) equity awards is consistent with best practices in executive compensation across the biotech industry, similar to companies like Amgen or Gilead Sciences, which often tie a significant portion of executive pay to company performance and stock appreciation.
• The vesting schedule for stock options (4-year monthly vesting) and RSUs (3-year annual vesting) is typical for executive grants in the U.S. market, comparable to structures seen at peer companies such as BioNTech or Moderna for their senior leadership.
• Tying PSU vesting to clinical milestones is a common and effective strategy in the biopharmaceutical sector, directly linking executive rewards to tangible R&D progress, a practice observed in companies developing new drug candidates.

Stakeholder Impact

• Shareholders: The grants are designed to align the Chief Business Officer's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: Standard executive compensation practices can positively influence overall employee morale and retention by demonstrating a commitment to rewarding key talent.

Next Steps

• Rachael Lester's continued service to CytomX Therapeutics.
• Achievement of specific clinical milestones for the vesting of Performance Stock Units.
• Annual vesting of Restricted Stock Units on March 15, starting March 15, 2027.
• Monthly vesting of stock options over the next four years.

Key Dates

Recommendation

This Form 4 filing reports routine equity compensation for a key executive and does not contain new operational, financial, or strategic information that would fundamentally alter the investment thesis for CytomX Therapeutics. While positive for management alignment, it does not warrant a change in investment recommendation based solely on this disclosure.

Keywords

CytomX Therapeutics, CTMX, Rachael Lester, Chief Business Officer, Form 4, SEC filing, Restricted Stock Units, RSUs, Stock Options, Performance Stock Units, PSUs, Equity Compensation, Insider Transaction, Executive Compensation, Vesting, Clinical Milestones